Developer docs
API playgroundTry for free, no card

Search company profiles

Monod Bio

Full company profile

uuid000068b

Namestring
Monod Bio
Legal namestring
Monod Bio, Inc.
Websiteurl
monod.bio
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Monod Bio is a Seattle-based life sciences company founded in 2022 as a spinout from David Baker's lab at the University of Washington's Institute for Protein Design. The company operates an AI-powered de novo protein design platform that computationally generates novel proteins from scratch — not derived from natural sequences — for use as research reagents and diagnostic building blocks. Its core platform combines generative design of protein sequences with optimization loops that tune properties such as binding affinity, thermal stability, manufacturability, and (for luciferases) brightness and glow kinetics.

The company's product portfolio spans three layers: (1) LuxSit™ Pro, the world's first commercially available fully de novo luciferase, offered as a whole-protein reporter and a split-pair system for protein-protein interaction studies; (2) NovoBody™ binders, ~27 kDa AI-designed proteins that serve as antibody replacements, available in Mono, bispecific Duo, and Fc-fusion formats; and (3) the NovoLISA™ homogeneous immunoassay platform, which pairs NovoBody capture reagents with LuxSit split luciferase reporting to deliver no-wash, mix-and-read results in under 15 minutes on standard plate readers, with a CRP assay launched in September 2024 and additional analytes (IL-6, TNF-alpha, IL-2, cTnI) in development. A LuxLink conjugation kit extends the platform to custom assay development. The technology has been validated in peer-reviewed publications in Nature and Nature Biotechnology and is the basis for the February 2026 commercial launch of Gator Bio's HIS XT biosensor probes — the first BLI probes built on AI-designed binding proteins.

Monod Bio operates a hybrid go-to-market model. Direct e-commerce (monod.bio) and global distribution through Fisher Scientific handle catalog RUO product sales at unit prices ranging from $125 to $750. The "Monod Inside" OEM/licensing model supplies NovoBody proteins to enterprise partners — notably Bio-Techne (exclusive licensing for NovoBody Duo, announced November 2025) and Gator Bio (BLI biosensor integration, with HIS XT probe launch in February 2026) — generating upfront payments, supply revenue, and royalties. The company also pursues non-dilutive capital through global health grants, including $2.25M from the Gates Foundation in 2025 for tuberculosis and preeclampsia diagnostics in low-resource settings. Its customer base spans academic and CRO researchers, life sciences tools and diagnostics companies (RUO/IVD), and global health organizations; pricing is unit-based with custom quotes for bulk/enterprise orders.

Short descriptiontext

Monod Bio is a Seattle-based life sciences company that uses AI to design de novo proteins, selling luciferase reporters, antibody-replacement binders, and biosensor assay platforms to life sciences researchers and diagnostics developers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
de novo protein design, luciferase assay reagents, antibody replacement proteins, homogeneous immunoassays, computational protein engineering
Industry2 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Life Sciences Research Reagents
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales
TypeOne Time License
Description

Sale of RUO (Research Use Only) products including LuxSit Pro luciferase kits, NovoBody binder proteins, NovoLISA assay kits, and LuxLink conjugation systems. Products sold directly and through distribution partners like Fisher Scientific.

monod.bio
2Licensing Royalties
TypeLicensing Royalties
Description

Licensing agreements with partners like Bio-Techne for exclusive commercial rights to NovoBody Duo molecules. Receives upfront, supply, and royalty payments from partners who commercialize products incorporating Monod's AI-designed proteins.

monod.bio
3Partnership Supply Revenue
TypeTransaction Fee
Description

Supply of NovoBody binding proteins to partners like Gator Bio for integration into their products. Monod receives supply payments and royalties for products commercialized by partners.

monod.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details6 tiers
1CRP NovoLISA - $450 per kit (96 tests)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

C-Reactive Protein detection assay. Detection range 0.02-20 µg/mL. Assay time: 15 min. Analytical sensitivity: 0.01 µg/mL. Sample volume: 5 µL.

monod.bio
2LuxSit™ Pro Luciferase Assay System - $750 (1000 reactions)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Whole luciferase enzyme kit including reaction buffer, substrate, and substrate reconstitution buffer. Optional plasmid encoding LuxSit Pro available.

monod.bio
3LuxSit™ sPro PPI System - Split luciferase for protein-protein interactions
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Two-component split reporter system for protein-protein interaction research and biosensor creation. Low assay background, high signal-to-noise upon reconstitution.

monod.bio
4His-Tag NovoBody™ Mono (MBIO-7973) - $350 (100 μg)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Twin-Strep-Tag format. Applications: ELISA, BLI, Capture. Also available as Biotin conjugate ($400) and FITC conjugate ($450).

monod.bio
5His-Tag NovoBody™ Duo (MBIO-8752) - $500 (100 μg)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Twin-Strep-Tag format. Applications: ELISA, Flow Cytometry, BLI, Capture. Also available as Biotin conjugate ($550) and FITC conjugate ($550). Contains single free cysteine for custom conjugation.

monod.bio
6Plasmids - $125-$250 each
ModelUnit PricingBilling cadencePay-as-you-go
Notes

LuxSit Pro N-term plasmid ($250), C-term plasmid ($250), Control plasmid ($150), ßit sPro N-term ($125), ßit sPro C-term, αLux sPro N-term, αLux sPro C-term, PPI Control Set (FRB:FKBP). 25 µg lyophilized format.

monod.bio
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1NovoBody
Description

AI-designed binding proteins that function as next-generation antibody replacements for research and diagnostics applications.

monod.bio
+3 more records
Core offering1 text field

Monod Bio designs, manufactures, and sells AI-engineered de novo proteins for life sciences research and diagnostics. Its core products include LuxSit Pro luciferase reporters, NovoBody binder proteins (antibody replacements), the NovoLISA homogeneous immunoassay platform, and LuxLink antibody conjugation kits, sold directly, through Fisher Scientific, and via OEM licensing to life sciences tools and diagnostics partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • LuxSit Pro is 150-fold brighter than its academic predecessor LuxSit
+3 more records
Product overview1 text field

Monod Bio offers a platform-plus-products architecture centered on AI-powered de novo protein design. The core technology enables rapid generation of novel proteins for diagnostics and life science tools. Key products include LuxSit Pro luciferase assay systems (whole protein and split formats for reporting and protein-protein interaction studies), NovoBody binder proteins (~27 kDa computationally designed binding molecules serving as antibody replacements in Mono, Duo, and Fc fusion formats), and the NovoLISA immunoassay platform combining NovoBody binders with LuxSit luciferase for rapid no-wash detection assays. LuxLink conjugation kits enable custom assay development. Products are sold direct and through distribution partners including Fisher Scientific, with commercial licensing of NovoBody Duo molecules to Bio-Techne and integration into Gator Bio's biosensor platform.

Product and service5 records
1LuxSit Pro Luciferase Assay System
CategoryProtein reporter reagents
Description

World's first fully de novo luciferase enzyme system available in whole-protein format, generating high-intensity glow-type luminescence with proprietary synthetic substrate and optimized reaction buffer for in vitro assays. Sold to life sciences researchers and OEM partners.

2LuxSit sPro Protein:Protein Interaction System
CategoryProtein reporter reagents
Description

Split LuxSit Pro luciferase reporter system composed of a small fragment (~1.5 kDa) and large fragment (~12 kDa) that reconstitute upon protein-protein interaction, enabling sensitive detection of PPIs for research and biosensor creation.

3NovoBody Binders
CategoryBinding proteins / antibody replacements
Description

AI-designed de novo protein binding molecules (~27 kDa) that function as next-generation antibody replacements, available in Mono, Duo (bispecific), and Fc fusion formats with high affinity (<nM), superior stability, and rapid custom development for research, biosensors, and diagnostic applications.

4NovoLISA Platform with CRP Assay
CategoryHomogeneous immunoassay kits
Description

Rapid no-wash homogeneous immunoassay platform combining NovoBody binders with LuxSit luciferase reporter, delivering results in under 15 minutes via a simple mix-and-read protocol. Currently offers a CRP assay; additional analytes (IL-6, TNF-alpha, IL-2, cTnI) in development.

5LuxLink for NovoLISA Conjugation System
CategoryAssay development reagents / conjugation kits
Description

Rapid antibody conjugation kit for custom NovoLISA assay development, enabling conjugation of LuxSit sPro fragments to antibody pairs in under four hours for simplified custom immunoassay development with minimal interference and high sensitivity.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-03
Description

Partnership to integrate Monod's AI-designed NovoBody binding proteins into Gator Bio's biolayer interferometry (BLI) biosensor platform. Monod supplies NovoBody proteins, Gator Bio handles manufacturing, sales, and marketing. Product launch anticipated in first half of 2026. Gator launched HIS XT probes with Monod's NovoBody technology in February 2026.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-18
Description

Licensing agreement granting Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody Duo molecules, AI-designed bispecific binding proteins. Partnership enhances Bio-Techne's portfolio for research and diagnostics with customizable proteins for advanced therapeutics development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-15
Description

$750,000 grant to develop point-of-care diagnostic test for preeclampsia using AI-designed proteins. Built on NovoLISA platform combining NovoBody binders and LuxSit luciferase. Aims to provide fast, affordable diagnosis for low-resource settings to improve maternal health outcomes.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

$1.5 million grant to develop rapid urine-based diagnostic test for tuberculosis using AI-designed NovoBodies. Test aims to improve TB detection in low-resource settings using lateral-flow assay format. Project addresses critical gaps where traditional sputum-based diagnostics are unavailable.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Monod Bio is a spinout from the David Baker Lab at UW IPD. Technology originated from research at this institution. David Baker serves as Scientific Advisor and co-founder.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Profluent applies AI to protein design and engineering, developing novel protein sequences from scratch using foundation models. Competes directly with Monod's AI-powered de novo protein design platform across research tools and therapeutic applications.

TypeDirect peer
Description

AbCellera is an AI-powered antibody discovery platform that partners with pharma to develop therapeutic antibodies. While focused on antibodies rather than de novo proteins, it competes for the same AI-driven binding protein opportunity Monod targets with NovoBody.

TypeDirect peer
Description

Generate Biomedicines is a generative biology company developing AI-designed protein therapeutics, with similar de novo protein design capabilities and a comparable platform-plus-pipeline model targeting therapeutics and diagnostics.

TypeDirect peer
Description

Cradle uses generative AI to design and optimize proteins for biotech applications, with a similar platform model serving life sciences researchers and bioengineering teams. Comparable in technology approach and customer segments to Monod's AI protein design capabilities.

TypeBroad incumbent
Description

Bio-Techne is a large life sciences reagents and tools company with extensive recombinant protein catalog, including antibodies and assay kits. Comparable as both a Monod licensing partner (NovoBody Duo) and a broad incumbent in the research reagent market Monod targets.

TypeBroad incumbent
Description

PerkinElmer provides a broad portfolio of life sciences research tools including immunoassay platforms, luminescence readers, and protein analysis reagents. Competes with Monod's NovoLISA platform across immunoassay and diagnostics applications.

TypeEmerging player
Description

Gator Bio manufactures biolayer interferometry (BLI) biosensors and is Monod's co-development partner for HIS XT probes incorporating NovoBody technology. Direct commercialization partner that brings Monod's protein designs into the biosensor market.

TypeBroad incumbent
Description

Promega is a major life sciences tools company offering luciferase reporters, protein interaction assays, and bioluminescence detection reagents that compete with LuxSit Pro. Direct incumbent in Monod's core RUO market for bioluminescent reporter tools.

TypeDirect peer
Description

Absci combines generative AI with synthetic biology to design novel protein therapeutics, including antibody alternatives. Overlaps with Monod in AI-driven protein design for research and therapeutic applications, though with a heavier therapeutic pipeline focus.

TypeEmerging player
Description

Neoleukin is a computational protein design company co-founded by Monod Bio's founders (Daniel Silva Manzano and Alfredo Quijano Rubio) that develops de novo cytokine mimetics for therapeutic applications. Sister company with shared founding team and overlapping technology origins.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Monod Bio

Life Sciences Research Reagentsmonod.bio

Monod Bio is a Seattle-based life sciences company that uses AI to design de novo proteins, selling luciferase reporters, antibody-replacement binders, and biosensor assay platforms to life sciences researchers and diagnostics developers.

What Monod Bio does

Monod Bio is a Seattle-based life sciences company founded in 2022 as a spinout from David Baker's lab at the University of Washington's Institute for Protein Design. The company operates an AI-powered de novo protein design platform that computationally generates novel proteins from scratch — not derived from natural sequences — for use as research reagents and diagnostic building blocks. Its core platform combines generative design of protein sequences with optimization loops that tune properties such as binding affinity, thermal stability, manufacturability, and (for luciferases) brightness and glow kinetics.

The company's product portfolio spans three layers: (1) LuxSit™ Pro, the world's first commercially available fully de novo luciferase, offered as a whole-protein reporter and a split-pair system for protein-protein interaction studies; (2) NovoBody™ binders, ~27 kDa AI-designed proteins that serve as antibody replacements, available in Mono, bispecific Duo, and Fc-fusion formats; and (3) the NovoLISA™ homogeneous immunoassay platform, which pairs NovoBody capture reagents with LuxSit split luciferase reporting to deliver no-wash, mix-and-read results in under 15 minutes on standard plate readers, with a CRP assay launched in September 2024 and additional analytes (IL-6, TNF-alpha, IL-2, cTnI) in development. A LuxLink conjugation kit extends the platform to custom assay development. The technology has been validated in peer-reviewed publications in Nature and Nature Biotechnology and is the basis for the February 2026 commercial launch of Gator Bio's HIS XT biosensor probes — the first BLI probes built on AI-designed binding proteins.

Monod Bio operates a hybrid go-to-market model. Direct e-commerce (monod.bio) and global distribution through Fisher Scientific handle catalog RUO product sales at unit prices ranging from $125 to $750. The "Monod Inside" OEM/licensing model supplies NovoBody proteins to enterprise partners — notably Bio-Techne (exclusive licensing for NovoBody Duo, announced November 2025) and Gator Bio (BLI biosensor integration, with HIS XT probe launch in February 2026) — generating upfront payments, supply revenue, and royalties. The company also pursues non-dilutive capital through global health grants, including $2.25M from the Gates Foundation in 2025 for tuberculosis and preeclampsia diagnostics in low-resource settings. Its customer base spans academic and CRO researchers, life sciences tools and diagnostics companies (RUO/IVD), and global health organizations; pricing is unit-based with custom quotes for bulk/enterprise orders.

Monod Bio firmographics

Firmographics
Name
Monod Bio
Legal name
Monod Bio, Inc.
Website
https://monod.bio
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Monod Bio is a Seattle-based life sciences company that uses AI to design de novo proteins, selling luciferase reporters, antibody-replacement binders, and biosensor assay platforms to life sciences researchers and diagnostics developers.
Ownership category
akta.pro rank

Monod Bio industry classification

Industry
Product category
Life Sciences Research Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • De novo protein design
  • Luciferase assay reagents
  • Antibody replacement proteins
  • Homogeneous immunoassays
  • Computational protein engineering

Where Monod Bio is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Monod Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Product Sales: Sale of RUO (Research Use Only) products including LuxSit Pro luciferase kits, NovoBody binder proteins, NovoLISA assay kits, and LuxLink conjugation systems. Products sold directly and through distribution partners like Fisher Scientific.
  2. Licensing Royalties: Licensing agreements with partners like Bio-Techne for exclusive commercial rights to NovoBody Duo molecules. Receives upfront, supply, and royalty payments from partners who commercialize products incorporating Monod's AI-designed proteins.
  3. Partnership Supply Revenue: Supply of NovoBody binding proteins to partners like Gator Bio for integration into their products. Monod receives supply payments and royalties for products commercialized by partners.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCRP NovoLISA - $450 per kit (96 tests)
Unit PricingPay-as-you-goLuxSit™ Pro Luciferase Assay System - $750 (1000 reactions)
Unit PricingPay-as-you-goLuxSit™ sPro PPI System - Split luciferase for protein-protein interactions
Unit PricingPay-as-you-goHis-Tag NovoBody™ Mono (MBIO-7973) - $350 (100 μg)
Unit PricingPay-as-you-goHis-Tag NovoBody™ Duo (MBIO-8752) - $500 (100 μg)
Unit PricingPay-as-you-goPlasmids - $125-$250 each

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Monod Bio product offering

Product offering

Core offering

Monod Bio designs, manufactures, and sells AI-engineered de novo proteins for life sciences research and diagnostics. Its core products include LuxSit Pro luciferase reporters, NovoBody binder proteins (antibody replacements), the NovoLISA homogeneous immunoassay platform, and LuxLink antibody conjugation kits, sold directly, through Fisher Scientific, and via OEM licensing to life sciences tools and diagnostics partners.

Product overview

Monod Bio offers a platform-plus-products architecture centered on AI-powered de novo protein design. The core technology enables rapid generation of novel proteins for diagnostics and life science tools. Key products include LuxSit Pro luciferase assay systems (whole protein and split formats for reporting and protein-protein interaction studies), NovoBody binder proteins (~27 kDa computationally designed binding molecules serving as antibody replacements in Mono, Duo, and Fc fusion formats), and the NovoLISA immunoassay platform combining NovoBody binders with LuxSit luciferase for rapid no-wash detection assays. LuxLink conjugation kits enable custom assay development. Products are sold direct and through distribution partners including Fisher Scientific, with commercial licensing of NovoBody Duo molecules to Bio-Techne and integration into Gator Bio's biosensor platform.

Differentiator

Problem solved

Functional benefit

Brands

  • NovoBody: AI-designed binding proteins that function as next-generation antibody replacements for research and diagnostics applications.
  • LuxSit Pro
  • NovoLISA
  • LuxLink

Products and services

  • LuxSit Pro Luciferase Assay System World's first fully de novo luciferase enzyme system available in whole-protein format, generating high-intensity glow-type luminescence with proprietary synthetic substrate and optimized reaction buffer for in vitro assays. Sold to life sciences researchers and OEM partners.
  • LuxSit sPro Protein:Protein Interaction System Split LuxSit Pro luciferase reporter system composed of a small fragment (~1.5 kDa) and large fragment (~12 kDa) that reconstitute upon protein-protein interaction, enabling sensitive detection of PPIs for research and biosensor creation.
  • NovoBody Binders AI-designed de novo protein binding molecules (~27 kDa) that function as next-generation antibody replacements, available in Mono, Duo (bispecific), and Fc fusion formats with high affinity (<nM), superior stability, and rapid custom development for research, biosensors, and diagnostic applications.
  • NovoLISA Platform with CRP Assay Rapid no-wash homogeneous immunoassay platform combining NovoBody binders with LuxSit luciferase reporter, delivering results in under 15 minutes via a simple mix-and-read protocol. Currently offers a CRP assay; additional analytes (IL-6, TNF-alpha, IL-2, cTnI) in development.
  • LuxLink for NovoLISA Conjugation System Rapid antibody conjugation kit for custom NovoLISA assay development, enabling conjugation of LuxSit sPro fragments to antibody pairs in under four hours for simplified custom immunoassay development with minimal interference and high sensitivity.

Quantifiable outcome

  • LuxSit Pro is 150-fold brighter than its academic predecessor LuxSit
  • +3 more outcomes

Companies that use Monod Bio

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Monod Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Monod Bio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Gator BiocoreStrategic or Co-development Partner · 3 December 2025Partnership to integrate Monod's AI-designed NovoBody binding proteins into Gator Bio's biolayer interferometry (BLI) biosensor platform. Monod supplies NovoBody proteins, Gator Bio handles manufacturing, sales, and marketing. Product launch anticipated in first half of 2026. Gator launched HIS XT probes with Monod's NovoBody technology in February 2026.
  • Bio-TechnecoreOEM/ Whitelabel/ Licensing Partner · 18 November 2025Licensing agreement granting Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody Duo molecules, AI-designed bispecific binding proteins. Partnership enhances Bio-Techne's portfolio for research and diagnostics with customizable proteins for advanced therapeutics development.
  • Gates Foundation Grand ChallengescoreStrategic or Co-development Partner · 15 October 2025$750,000 grant to develop point-of-care diagnostic test for preeclampsia using AI-designed proteins. Built on NovoLISA platform combining NovoBody binders and LuxSit luciferase. Aims to provide fast, affordable diagnosis for low-resource settings to improve maternal health outcomes.
  • Gates FoundationcoreStrategic or Co-development Partner · 3 September 2025$1.5 million grant to develop rapid urine-based diagnostic test for tuberculosis using AI-designed NovoBodies. Test aims to improve TB detection in low-resource settings using lateral-flow assay format. Project addresses critical gaps where traditional sputum-based diagnostics are unavailable.
  • University of Washington Institute for Protein DesigncoreStrategic or Co-development PartnerMonod Bio is a spinout from the David Baker Lab at UW IPD. Technology originated from research at this institution. David Baker serves as Scientific Advisor and co-founder.

Scale indicators6 records

Recent moves7 records

Expansion highlights7 records

Monod Bio competitors and assessment

Company assessment

Direct peers

  • Profluent Bio: Profluent applies AI to protein design and engineering, developing novel protein sequences from scratch using foundation models. Competes directly with Monod's AI-powered de novo protein design platform across research tools and therapeutic applications.
  • AbCellera Biologics: AbCellera is an AI-powered antibody discovery platform that partners with pharma to develop therapeutic antibodies. While focused on antibodies rather than de novo proteins, it competes for the same AI-driven binding protein opportunity Monod targets with NovoBody.
  • Generate Biomedicines: Generate Biomedicines is a generative biology company developing AI-designed protein therapeutics, with similar de novo protein design capabilities and a comparable platform-plus-pipeline model targeting therapeutics and diagnostics.
  • Cradle Bio: Cradle uses generative AI to design and optimize proteins for biotech applications, with a similar platform model serving life sciences researchers and bioengineering teams. Comparable in technology approach and customer segments to Monod's AI protein design capabilities.
  • Absci: Absci combines generative AI with synthetic biology to design novel protein therapeutics, including antibody alternatives. Overlaps with Monod in AI-driven protein design for research and therapeutic applications, though with a heavier therapeutic pipeline focus.

Broad incumbents

  • Bio-Techne: Bio-Techne is a large life sciences reagents and tools company with extensive recombinant protein catalog, including antibodies and assay kits. Comparable as both a Monod licensing partner (NovoBody Duo) and a broad incumbent in the research reagent market Monod targets.
  • PerkinElmer: PerkinElmer provides a broad portfolio of life sciences research tools including immunoassay platforms, luminescence readers, and protein analysis reagents. Competes with Monod's NovoLISA platform across immunoassay and diagnostics applications.
  • Promega Corporation: Promega is a major life sciences tools company offering luciferase reporters, protein interaction assays, and bioluminescence detection reagents that compete with LuxSit Pro. Direct incumbent in Monod's core RUO market for bioluminescent reporter tools.

Emerging players

  • Gator Bio: Gator Bio manufactures biolayer interferometry (BLI) biosensors and is Monod's co-development partner for HIS XT probes incorporating NovoBody technology. Direct commercialization partner that brings Monod's protein designs into the biosensor market.
  • Neoleukin Therapeutics: Neoleukin is a computational protein design company co-founded by Monod Bio's founders (Daniel Silva Manzano and Alfredo Quijano Rubio) that develops de novo cytokine mimetics for therapeutic applications. Sister company with shared founding team and overlapping technology origins.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Monod Bio social profiles

Digital presence

Monod Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Monod Bio leadership team

Management profile

Number of profiles

Profiles12 records

Monod Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Monod Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monod Bio

What does Monod Bio do?

Monod Bio designs, manufactures, and sells AI-engineered de novo proteins for life sciences research and diagnostics. Its core products include LuxSit Pro luciferase reporters, NovoBody binder proteins (antibody replacements), the NovoLISA homogeneous immunoassay platform, and LuxLink antibody conjugation kits, sold directly, through Fisher Scientific, and via OEM licensing to life sciences tools and diagnostics partners.

Is Monod Bio a public or private company?

Monod Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Monod Bio founded?

Monod Bio was founded in 2022. It employs 11 to 50 people.

Where is Monod Bio based?

Monod Bio is headquartered in Seattle, United States, in the North America region.

How does Monod Bio make money?

Three revenue lines are on record. Product Sales are the primary driver. The others are licensing Royalties and partnership Supply Revenue.

Who are Monod Bio's main competitors?

Direct peers on record are Profluent Bio, AbCellera Biologics, Generate Biomedicines, Cradle Bio and Absci. Broad incumbents are Bio-Techne, PerkinElmer and Promega Corporation. Emerging players are Gator Bio and Neoleukin Therapeutics.

Does Monod Bio have an API?

No public API is recorded for Monod Bio.

What industry is Monod Bio in?

Monod Bio's product category is Life Sciences Research Reagents. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireQVQ Licenses Monod Bio's LuxSit™ Pro Luciferase to Measure Target Engagement of Single-Domain AntibodiesQVQ and Monod Bio announced a non-exclusive licensing agreement for Monod Bio's LuxSit Pro de novo luciferase and its split components. QVQ will incorporate the technology into fee-for-service, research-use-only assays to screen and characterize single-domain antibody target binding. The agreement expands QVQ's molecular pharmacology and lead discovery services.PR NewswireBPS Bioscience Licenses Monod Bio's AI-Designed Proteins to Develop Novel Research Products and ServicesMonod Bio and BPS Bioscience announced a non-exclusive licensing agreement covering Monod's LuxSit Pro luciferase and NovoBody binders. BPS will integrate these AI-designed proteins into future research products and services for drug discovery. Specific offerings are expected to be announced later.News-MedicalMonod Bio licenses AI-designed protein technologies to SignalChem Biotech for custom discovery assaysMonod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech, a wholly-owned subsidiary of Sino Biological, announced a non-exclusive licensing agreement covering Monod Bio's LuxSit de novo luciferase technology and NovoBodies. SignalChem may use the technologies in custom luminescent assay development and protein-fusion services for third-party research customers. Financial terms were not disclosed.YahooMonod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery AssaysMonod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech, a wholly-owned subsidiary of Sino Biological, announced a non-exclusive licensing agreement on August 26, 2026 covering Monod Bio's LuxSit de novo luciferase and NovoBodies. SignalChem may use the technologies in custom luminescent assay development and protein-fusion services for third-party research customers. Financial terms were not disclosed.FinancialContent Business PageMonod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery AssaysSino Biological's SignalChem Biotech has licensed Monod Bio's AI-designed LuxSit luciferase and NovoBodies technologies for use in custom luminescent assay development and protein-fusion services. The agreement lets SignalChem incorporate the tools into third-party research offerings, expanding its CRO capabilities. Financial terms were not disclosed.PR Newswire APACMonod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery AssaysMonod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech, a wholly-owned subsidiary of Sino Biological, announced a non-exclusive licensing agreement covering Monod Bio's LuxSit de novo luciferase and NovoBodies technologies. SignalChem may use the technologies in custom luminescent assay development and protein-fusion services for third-party research customers. Financial terms were not disclosed.PR NewswireMonod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery AssaysMonod Bio, a Seattle-based AI protein design company, and SignalChem Biotech, a wholly-owned subsidiary of Sino Biological, announced a non-exclusive licensing agreement covering Monod Bio's LuxSit de novo luciferase and NovoBodies technologies. SignalChem may use the technologies in custom luminescent assay development and protein-fusion services for third-party research customers. Financial terms were not disclosed.BioSpaceMonod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery AssaysMonod Bio and SignalChem Biotech announced a non-exclusive licensing agreement for Monod Bio's LuxSit luciferase and NovoBodies technologies. SignalChem may use them in custom luminescent assays and protein-fusion services for third-party customers. The partnership expands SignalChem's CRO capabilities and supports Sino Biological's AI-enabled technology strategy.PR NewswireMonod Bio Announces Appointment of Robert J. Bujarski to Board of DirectorsMonod Bio, a Seattle-based computational protein design company and spinout from the University of Washington's Institute for Protein Design, announced the appointment of Robert J. Bujarski to its Board of Directors. Bujarski brings over 20 years of industry experience, most recently serving as Executive Vice President and Chief Operating Officer at QuidelOrtho Corporation, where he played a central role in scaling the company from $60 million to over $3 billion in annual sales. His expertise in regulatory navigation and strategic mergers is expected to support Monod Bio's expansion of its AI-powered protein design platform and commercialization of its NovoBody™ technology.Investing.comBenchmark maintains Buy rating on Bio-Techne stock ahead of earnings By Investing.comBenchmark maintained its Buy rating and $75.00 price target on Bio-Techne Corporation ahead of the company's Q2 FY2026 earnings report scheduled for February 4, with the target implying 15.5% upside from the current price of $64.92. The firm forecasts Bio-Techne will report revenues of $294 million, representing a 1% year-over-year decrease, with adjusted EPS remaining flat at $0.42. Bio-Techne has recently launched new products including the Cultrex Synthetic Hydrogel and Simple Plex Ultra-Sensitive Assays, and secured a licensing agreement with Monod Bio for exclusive commercial rights to NovoBody Duo molecules.